USA-based AcelRx Pharmaceuticals (Nasdaq: ACRX) revealed this morning that its partner, family-owned German drugmaker Grunenthal, has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for Zalviso (ARX-01) for the management of moderate to severe acute pain in adult patients in a medically supervised environment.AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) net profit margin is -70.40% and weekly performance is 8.88%. On last trading day company shares ended up $11.16. Analysts mean target price for the company is $16.94. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) distance from 50-day simple moving average is 13.31%.
On June 12,2014 Sprint (NYSE:S) was upgraded by equities research analysts at Macquarie from a “neutral” rating to an “outperform” rating in a research note issued to investors on Tuesday, Sprint Corporation (NYSE:S) shares fell -1.16% in last trading session and ended the day on $8.50. S Gross Margin is 44.00% and its return on assets is -3.10%. Sprint Corporation (NYSE:S) quarterly performance is -8.21%.
EMC Corporation (NYSE:EMC) remains under pressure in the Storage sector. The stock has also traded back and forth over the past month. However, there are still opportunities in the stock that can make patient investors rich, at least if the recent revelation by Becker Capital Management is anything to consider. EMC Corporation (NYSE:EMC) shares moved down -0.22% in last trading session and was closed at $26.86, while trading in range of $26.73-$26.93. EMC Corporation (NYSE:EMC) year to date performance is 8.09%.
The Celldex Therapeutics, Inc. (NASDAQ:CLDX) on June 2 reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended the last trading day at $15.76. Company weekly volatility is calculated as 6.36% and price to cash ratio as 5.14. Celldex Therapeutics, Inc. (NASDAQ:CLDX) showed a negative weekly performance of -5.17%.